ESR1 and breast cancer: Furthermore, xu et al. conducted a phase III PALOMA-4 trial in Asian postmenopausal women with ER-positive/HER2-negative advanced breast cancer in 2022 and found that the most common serious AEs in the palbociclib arm were infections (Xu et al., 2022).